Core Viewpoint - LuKang Pharmaceutical (600789.SH) expects a significant decline in net profit for the fiscal year 2025, projecting a net profit attributable to shareholders of the parent company between 110 million to 145 million yuan, representing a decrease of approximately 249.62 million to 284.62 million yuan compared to the previous year, which translates to a year-on-year decline of 63.26% to 72.13% [1] Financial Summary - The projected net profit for 2025 is estimated to be between 110 million to 145 million yuan [1] - The expected decrease in net profit compared to the previous year is between 249.62 million to 284.62 million yuan [1] - The year-on-year percentage decline in net profit is forecasted to be between 63.26% and 72.13% [1]

Group 1 - The company, Lu Kang Pharmaceutical (600789.SH), expects to achieve a net profit attributable to shareholders of the parent company between 110 million to 145 million yuan for the fiscal year 2025 [1] - This represents a decrease of 249.62 million to 284.62 million yuan compared to the previous year [1] - The year-on-year decline in net profit is projected to be between 63.26% to 72.13% [1]

证券代码:600789 证券简称:鲁抗医药 公告编号:2026-005 ●预计 2025 年度实现归属于母公司所有者的净利润 11,000 万元-14,500 万 元。与上年同期相比，同比减少 63.26%-72.13%。 ●预计 2025 年度实现归属于母公司所有者的扣除非经常性损益的净利润 8,000万元-11,800 万元。与上年同期相比，同比减少 43.43%-61.65%。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 山东鲁抗医药股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●本期业绩预告适用于实现盈利，且净利润与上年同期相比下降50%以上的情 形。 三、本期业绩预减的主要原因 （一）非经常性损益的影响。上年同期公司南厂区土地办理完成移交手续， 土地完成整体移交后产生大额的资产处置收益，导致本期业绩较上年同期变动幅 度较大。 （二）市场因素影响。受产品市场需求放缓、行业竞争激 ...

每经AI快讯，1月27日，鲁抗医药（600789）(600789.SH)公告称，鲁抗医药预计2025年度归属于上市公 司股东的净利润为1.10亿元-1.45亿元，同比减少63.26%-72.13%。业绩变动原因：上年同期南厂区土地 移交产生大额资产处置收益；市场需求放缓、集采降价致量价承压；研发及技术资产摊销投入增加。 ...

证券之星消息，1月26日化学制药板块较上一交易日下跌0.18%，富祥药业领跌。当日上证指数报收于 4132.61，下跌0.09%。深证成指报收于14316.64，下跌0.85%。化学制药板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日化学制药板块主力资金净流入11.16亿元，游资资金净流入2.2亿元，散户资金净 流出13.37亿元。化学制药板块个股资金流向见下表： | 代码 | 名称 | 主力净流入 (元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 600789 | 鲁抗医药 | 26653 | 29.72% | -1.98亿 | -14.72% | -2.01 乙 | -14.99% | | 300723 | 一品红 | 1.00 Z | 13.23% | 2678.72万 | 3.54% | -1.27 Z | -16.76% ...

Market Overview - The Shanghai Composite Index experienced a sideways movement, while the Shenzhen Component Index and ChiNext Index fell nearly 1%. The trading volume reached 3.28 trillion yuan, with nearly 3,800 stocks declining across the Shanghai and Shenzhen markets [1] - Precious metals stocks surged, with companies like Zhongjin Gold and Western Gold hitting the daily limit. The pharmaceutical sector also saw strong performance, with stocks such as Capstone Bio and Maike Bio reaching the daily limit [1] Key Highlights Precious Metals - Gold and silver stocks saw significant gains, with multiple stocks like Silver Nonferrous and Sichuan Gold hitting the daily limit. On January 26, spot gold surged, breaking the $5,000 mark in the morning and later surpassing $5,100 per ounce, setting a new historical high [4] - Companies such as Zhongjin Gold and Western Gold reported increases of 10% and 9.99% respectively, with market capitalizations of 159.96 billion yuan and 334.91 billion yuan [6][10] Pharmaceuticals - The pharmaceutical sector experienced a notable rise, with stocks like Teva Pharmaceutical, Hualan Biological Engineering, and Luyin Pharmaceutical reaching the daily limit. The sector's performance was influenced by the recent outbreak of the Nipah virus in India, prompting increased vigilance in neighboring countries [8][9] - Teva Pharmaceutical's stock rose by 10.01%, while Hualan Biological Engineering surged by 20% [10] Cloud Computing - The cloud computing sector saw an uptick, with stocks like Hasen Co., Qunxing Toys, and Wangsu Technology hitting the daily limit. Amazon Web Services recently raised its EC2 machine learning capacity block prices by approximately 15%, indicating a significant shift in cloud computing pricing logic amid AI resource shortages [12][14] - Analysts predict that this price increase may trigger a chain reaction among cloud service providers, with domestic and international companies likely to follow suit [12][14] Other Sectors - The oil and gas sector saw a midday rally, with Zhongman Petroleum hitting the daily limit and China National Offshore Oil Corporation rising over 6% to reach a new high. However, the commercial aerospace concept experienced adjustments, with stocks like China Satellite and China Satcom hitting the daily limit [1] - The robotics and photovoltaic sectors showed mixed performance, while aerospace and semiconductor sectors faced the largest declines [14]

据世界卫生组织等机构介绍，尼帕病毒能攻击人的肺部和大脑，症状包括发烧、头疼、嗜睡、意识模糊 和昏迷，感染者的死亡率可达40%以上。这种病毒从感染到出现症状的潜伏期一般为4天至14天，最长 可达45天。目前尚无专门针对尼帕病毒的疫苗和有效疗法。 据新华社，泰国民航局宣布，1月26日起对来自印度西孟加拉邦的航班进行全面筛查，以防止尼帕病毒 输入泰国。筛查从26日0时起开始实施，同时将根据形势发展随时调整。 编辑丨瑜见 | 代码 | 名称 | 张唱 | 总金额 | 总市值 | 现价 | | --- | --- | --- | --- | --- | --- | | 300463 | 迈克生物 | +20.03% | 7666.6 | 85.86 Z | 14.20 | | 300638 | 凯普生物 | +20.03% | 3.36 Z | 46.87 G | 7.25 | | 688317 | 之江生物 | +20.01% | 3.20 乙 | 49.10 Z | 25.55 | | 301207 | 华兰疫苗 | +20.00% | 5.75 G | 140.3 Z | 23.34 | | 688670 | 金 ...

据新华社，泰国民航局宣布，1月26日起对来自印度西孟加拉邦的航班进行全面筛查，以防止尼帕病毒 输入泰国。筛查从26日0时起开始实施，同时将根据形势发展随时调整。 编辑丨瑜见 据央视新闻，近期，印度东部的西孟加拉邦出现尼帕病毒感染病例，目前已有5例确诊病例，其中包括 医护人员。据悉，近100人被要求居家隔离，感染者正在该邦首府加尔各答及周边医院接受治疗，其中 一名患者病情危重。 据世界卫生组织等机构介绍，尼帕病毒能攻击人的肺部和大脑，症状包括发烧、头疼、嗜睡、意识模糊 和昏迷，感染者的死亡率可达40%以上。这种病毒从感染到出现症状的潜伏期一般为4天至14天，最 长可达45天。目前尚无专门针对尼帕病毒的疫苗和有效疗法。 1月26日，流感板块午后拉升，截至发稿，迈克生物、凯普生物、之江生物、华兰疫苗20%涨停，达 安基因、特一药业、鲁抗医药、科华生物等涨停，智飞生物、万孚生物、康希诺、沃森生物等涨超 10%。 ...

Group 1 - The core point of the article is that LuKang Pharmaceutical announced the use of idle raised funds to temporarily supplement its working capital [2] - The company will utilize 200 million yuan of temporarily idle raised funds for this purpose [2] - The approval for this decision was made during the 12th (temporary) meeting of the 11th Board of Directors held on January 23, 2026 [2] Group 2 - The duration for using the funds is set to be no more than 12 months from the date of the board's approval [2]

Core Viewpoint - The company, LuKang Pharmaceutical, has announced a plan to utilize part of its idle raised funds for cash management, ensuring that it does not affect the normal operation of investment projects [2] Group 1: Company Announcement - On January 23, 2026, LuKang Pharmaceutical held the twelfth (temporary) meeting of the eleventh board of directors to approve the proposal for cash management using idle raised funds [2] - The company will use an amount not exceeding RMB 31 million for cash management, with a validity period of 12 months from the date of board approval [2] - A dedicated settlement account for cash management products has been opened at the Jining Jin Yu Road Branch of China Postal Savings Bank [2]